Is Bristol Myers Squibb A Buy At These Bottom Levels?

DNY59 We previously discussed Bristol Myers Squibb Company (NYSE:BMY) in December 2023, discussing why our previous Hold rating had proven to be prudent, with the stock losing -12.35% of its value since then. Combined with the sustained top-line erosion from Revlimid's LOE, upcoming Eliquis LOE by 2026, and the potential balance sheet deterioration after the aggressive M&A activities, we believed that it might be more prudent to observe the stock's movement for a little longer. In this article, we shall dis ...